Centaurus Financial Inc. Has $3.64 Million Stake in Axon Enterprise, Inc $AXON

Centaurus Financial Inc. reduced its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 25.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 5,074 shares of the biotechnology company’s stock after selling 1,710 shares during the period. Centaurus Financial Inc.’s holdings in Axon Enterprise were worth $3,642,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of AXON. Brighton Jones LLC bought a new stake in Axon Enterprise during the fourth quarter worth $480,000. NewEdge Advisors LLC lifted its stake in Axon Enterprise by 41.1% during the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after acquiring an additional 668 shares in the last quarter. Empowered Funds LLC boosted its holdings in Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after acquiring an additional 157 shares during the last quarter. Woodline Partners LP boosted its holdings in Axon Enterprise by 40.6% during the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after acquiring an additional 2,003 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in shares of Axon Enterprise in the 2nd quarter worth $284,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axon Enterprise

In related news, CAO Jennifer H. Mak sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total value of $860,175.00. Following the transaction, the chief accounting officer owned 12,240 shares in the company, valued at approximately $7,019,028. This represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total value of $5,002,400.00. Following the transaction, the chief executive officer directly owned 3,090,997 shares of the company’s stock, valued at approximately $1,546,240,339.28. This trade represents a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 24,832 shares of company stock valued at $13,903,398 over the last quarter. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $508.41 on Thursday. The company has a market capitalization of $40.88 billion, a P/E ratio of 334.48, a price-to-earnings-growth ratio of 10.81 and a beta of 1.46. The company’s 50-day moving average is $524.40 and its 200 day moving average is $603.77. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53. Axon Enterprise, Inc has a fifty-two week low of $396.41 and a fifty-two week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the company posted $2.08 earnings per share. On average, equities research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Stronger recurring revenue outlook — analysts and industry write-ups highlight that Axon’s Software & Services segment grew rapidly (~40% y/y in 2025), boosting subscriptions and recurring revenue visibility, which supports higher forward multiples. Axon’s Software & Services Strength in Focus
• Positive Sentiment: Ongoing municipal demand — recent local-government purchases/grants (Decatur $1.97M grant for DPD tech; Yavapai County approves Tasers funding) point to steady device and evidence-management adoption at the municipal level, supporting hardware + services revenue streams. Decatur grant article Yavapai County Tasers
• Positive Sentiment: Institutional interest noted — coverage/mentions (e.g., Baron Capital referenced in investor letters) signal investor interest from growth-focused funds, which can underpin demand for the stock. Baron Capital mention
• Neutral Sentiment: High retail/investor attention — multiple “trending” and comparative performance pieces are circulating, increasing short-term volume and volatility but not signaling a clear directional catalyst. Trending stock write-up
• Neutral Sentiment: Short-interest data appears unreliable — recent reports show “0 shares” and NaN changes, so there’s no actionable signal from the published short-interest figures; treat these data points cautiously.
• Negative Sentiment: Insider sale — Director Erika Nardini sold 198 shares (~$100k) and reduced her stake; while size is modest relative to market cap, insider sales can create short-term negative perception. SEC Form 4
• Negative Sentiment: Recent price weakness and skepticism — coverage (e.g., Forbes) documents a multi-day selloff and questions about whether Axon’s high-growth narrative has paused, which pressures near-term sentiment. Forbes analysis
• Negative Sentiment: Recent intraday/near-term pullbacks reported — some market write-ups note recent declines, adding to short-term volatility risk for momentum-driven holders. Yahoo Markets

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AXON. Piper Sandler dropped their price target on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Needham & Company LLC reduced their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Robert W. Baird set a $800.00 target price on shares of Axon Enterprise in a research report on Wednesday, February 25th. Finally, Craig Hallum restated a “buy” rating and issued a $820.00 target price on shares of Axon Enterprise in a research note on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus price target of $762.93.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.